

Alfa-arbutin 0.5% to 2.0% in Cleoderm™ Cream Base Alfa-bisabolol 0.5% to 2.0% in Cleoderm™ Cream Base Ascorbic Acid 5.0% to 20.0% in Cleoderm™ Cream Base Azelaic Acid 10.0% to 25.0% in Cleoderm™ Cream Base Alfa-arbutin 0.5% to 2.0% in Cleoderm™ Cream Base Alfa-bisabolol 0.5% to 2.0% in Cleoderm™ Cream Base Ascorbic Acid 5.0% to 20.0% in Cleoderm™ Cream Base Azelaic Acid 10.0% to 25.0% in Cleoderm™ Cream Base Benzoyl Peroxide 2.5% to 10.0% in Cleoderm™ Cream Base Brimonidine 0.2% to 0.5% in Cleoderm™ Cream Base Clindamycin (Phosphate) 1.0% to 3.0% in Cleoderm™ Cream Base Clofazimine 0.5% to 1.0% in Cleoderm™ Cream Base Cysteamine 5.0% in Cleoderm™ Cream Base Enoxolone 0.5% to 2.5% in Cleoderm™ Cream Base Estriol 0.1% to 1.0% in Cleoderm™ Cream Base Flutamide 2.0% to 2.5% in Cleoderm™ Cream Base Hydroquinone 2.0% to 10.0% in Cleoderm™ Cream Base Isotretinoin 0.05% in Cleoderm™ Cream Base



# Cleoderm™

## Formulary

Version 3.0



## Summary

<b>Introduction</b> .....	6
<b>Cleoderm™, Skin rebalancing cream</b> .....	6
<b>Meet the Cleoderm™ ingredients</b> .....	7
<b>Compounding with Cleoderm™</b> .....	9

### APIs and DCIs

Adapalene 0.1% to 0.3% in Cleoderm™ Cream Base .....	12
Alfa-arbutin 0.5% to 2.0% in Cleoderm™ Cream Base .....	13
Alfa-bisabolol 0.5% to 2.0% in Cleoderm™ Cream Base .....	14
Ascorbic Acid 5.0% to 20.0% in Cleoderm™ Cream Base .....	15
Azelaic Acid 10.0% to 25.0% in Cleoderm™ Cream Base .....	16
Benzoyl Peroxide 2.5% to 10.0% in Cleoderm™ Cream Base .....	17
Brimonidine 0.2% to 0.5% in Cleoderm™ Cream Base .....	18
Clindamycin (Phosphate) 1.0% to 3.0% in Cleoderm™ Cream Base .....	19
Clobetasol Propionate 0.5% in Cleoderm™ Cream Base .....	20
Cyproterone Acetate 0.5% to 2.0% in Cleoderm™ Cream Base .....	21
Cysteamine 5.0% in Cleoderm™ Cream Base .....	22
Dapsone 5.0% to 10.0% in Cleoderm™ Cream Base .....	23
Ellagic Acid 0.25% to 1.0% in Cleoderm™ Cream Base .....	24
Enoxolone 0.5% to 2.5% in Cleoderm™ Cream Base .....	25
Erythromycin 1.0% to 4.0% in Cleoderm™ Cream Base .....	26
Estriol 0.1% to 1.0% in Cleoderm™ Cream Base .....	27
Flutamide 2.0% to 2.5% in Cleoderm™ Cream Base .....	28
Glycolic Acid 2.0% to 10.0% in Cleoderm™ Cream Base .....	29
Hydroquinone 2.0% to 10.0% in Cleoderm™ Cream Base .....	30
Isotretinoin 0.05% in Cleoderm™ Cream Base .....	31
Kojic Acid 1.0% to 4.0% in Cleoderm™ Cream Base .....	32
Mandelic Acid 2.0% to 10.0% in Cleoderm™ Cream Base .....	33
Metronidazole 0.75% to 5.0% in Cleoderm™ Cream Base .....	34
Miconazole Nitrate 0.25% to 2.0% in Cleoderm™ Cream Base .....	35
N-Acetylcysteine 3.0% to 5.0% in Cleoderm™ Cream Base .....	36
Niacinamide 1.0% to 5.0% in Cleoderm™ Cream Base .....	37
Permethrin 1.0% to 5.0% in Cleoderm™ Cream Base .....	38
Phytic Acid 2.0% in Cleoderm™ Cream Base .....	39
Progesterone 0.5% to 2.0% in Cleoderm™ Cream Base .....	40
Silymarin 1.0% to 16.0% in Cleoderm™ Cream Base .....	41
Spironolactone 1.0% to 5.0% in Cleoderm™ Cream Base .....	42
Tazarotene 0.045% to 0.1% in Cleoderm™ Cream Base .....	43
Tranexamic Acid 1.0% to 5.0% in Cleoderm™ Cream Base .....	44



Tretinoin 0.01% to 0.1% in Cleoderm™ Cream Base .....	45
Zinc Acetate 1.2% to 1.5% in Cleoderm™ Cream Base .....	46
Zinc Pyrithione 0.5% to 2.0% in Cleoderm™ Cream Base .....	47

**APIs and DCIs Associations ..... 49**

Adapalene 0.1% and Benzoyl Peroxide 1.0% in Cleoderm™ Cream Base .....	50
Adapalene 0.3% and Benzoyl Peroxide 10.0% in Cleoderm™ Cream Base .....	51
Adapalene 0.15%, Clindamycin (Phosphate) 1.2%, and Benzoyl Peroxide 3.1% in Cleoderm™ Cream Base .....	52
Alfa-arbutin 0.5% and Ascorbic Acid 5.0% in Cleoderm™ Cream Base .....	53
Alfa-arbutin 0.5% and Glycolic Acid 2.0% in Cleoderm™ Cream Base .....	54
Alfa-arbutin 0.5% and Hydroquinone 2.0% in Cleoderm™ Cream Base .....	55
Alfa-arbutin 0.5% and Kojic Acid 1.0% in Cleoderm™ Cream Base .....	56
Alfa-arbutin 0.5% and Mandelic Acid 2.0% in Cleoderm™ Cream Base .....	57
Alfa-arbutin 0.5% and Phytic Acid 0.05% in Cleoderm™ Cream Base .....	58
Alfa-bisabolol 0.5% and Glycolic Acid 2.0% in Cleoderm™ Cream Base .....	59
Alfa-bisabolol 0.5% and Tretinoin 0.01% in Cleoderm™ Cream Base .....	60
Ascorbic Acid 5.0% and Glycolic Acid 2.0% in Cleoderm™ Cream Base .....	61
Ascorbic Acid 5.0% and Niacinamide 1.0% in Cleoderm™ Cream Base .....	62
Ascorbic Acid 5.0% and Salicylic Acid 0.5% in Cleoderm™ Cream Base .....	63
Azelaic Acid 10.0% and Erythromycin 1.0% in Cleoderm™ Cream Base .....	64
Azelaic Acid 10.0% and Niacinamide 1.0% in Cleoderm™ Cream Base .....	65
Azelaic Acid 15.0% and Niacinamide 4.0% in Cleoderm™ Cream Base .....	66
Benzoyl Peroxide 2.5% and Erythromycin 1.0% in Cleoderm™ Cream Base .....	67
Clindamycin (Phosphate) 1.0% and Adapalene 0.1% in Cleoderm™ Cream Base .....	68
Clindamycin (Phosphate) 1.0%, Benzoyl Peroxide 1.0%, and Niacinamide 1.0% in Cleoderm™ Cream Base .....	69
Clindamycin (Phosphate) 3.0%, Benzoyl Peroxide 10.0%, and Niacinamide 4.0% in Cleoderm™ Cream Base .....	70
Clindamycin (Phosphate) 1.0% and Hydroquinone 4.0% in Cleoderm™ Cream Base .....	71
Clindamycin (Phosphate) 1.0% and Tretinoin 0.01% in Cleoderm™ Cream Base .....	72
Clobetasol Propionate 0.05%, Hydroquinone 2.0%, and Tretinoin 0.01% in Cleoderm™ Cream Base .....	73
Cysteamine 5.0% and Niacinamide 1.0% in Cleoderm™ Cream Base .....	74
Cysteamine 5.0% and Tranexamic Acid 1.0% in Cleoderm™ Cream Base .....	75
Dapsone 5.0% and Adapalene 0.1% in Cleoderm™ Cream Base .....	76
Enoxolone 0.5% and Glycolic Acid 2.0% in Cleoderm™ Cream Base .....	77
Enoxolone 0.5% and Metronidazole 0.75% in Cleoderm™ Cream Base .....	78
Enoxolone 0.5% and Tretinoin 0.01% in Cleoderm™ Cream Base .....	79



Glycolic Acid 2.0% and Clindamycin (Phosphate) 1.0% in Cleoderm™ Cream Base .....	80
Glycolic Acid 2.0% and Erythromycin 1.0% in Cleoderm™ Cream Base .....	81
Glycolic Acid 5.0%, Gluconolactone 2.5%, Mandelic Acid 2.5%, and Salicylic Acid 0.5% in Cleoderm™ Cream Base .....	82
Glycolic Acid 2.0% and Tretinoin 0.01% in Cleoderm™ Cream Base .....	83
Hydrocortisone 1.0%, Hydroquinone 4.0%, Tranexamic Acid 2.5%, and Tretinoin 0.0125% in Cleoderm™ Cream Base .....	84
Hydrocortisone 1.0%, Hydroquinone 4.0%, Tranexamic Acid 2.5%, and Tretinoin 0.035% in Cleoderm™ Cream Base .....	85
Isotretinoin 0.05% and Erythromycin 2.0% in Cleoderm™ Cream Base .....	86
Mandelic Acid 2.0% and Benzoyl Peroxide 2.5% in Cleoderm™ Cream Base .....	87
Mandelic Acid 2.0% and Tretinoin 0.01% in Cleoderm™ Cream Base .....	88
Metronidazole 0.75% and Alfa-bisabolol 0.5% in Cleoderm™ Cream Base .....	89
Metronidazole 0.75% and Azelaic Acid 1.0% in Cleoderm™ Cream Base .....	90
Metronidazole 0.75% and Clindamycin (Phosphate) 1.0% in Cleoderm™ Cream Base .....	91
Metronidazole 0.75% and Erythromycin 1.0% in Cleoderm™ Cream Base .....	92
Metronidazole 0.75% and Niacinamide 1.0% in Cleoderm™ Cream Base .....	93
Metronidazole 2.0% and Niacinamide 5.0% in Cleoderm™ Cream Base .....	94
Metronidazole 0.75% and Tretinoin 0.01% in Cleoderm™ Cream Base .....	95
Miconazole (Nitrate) 0.25% and Benzoyl Peroxide 2.5% in Cleoderm™ Cream Base .....	96
Miconazole (Nitrate) 0.25% and Erythromycin 1.0% in Cleoderm™ Cream Base .....	97
Miconazole (Nitrate) 0.25% and Zinc Oxide 10.0% in Cleoderm™ Cream Base .....	98
Permethrin 1.0% and Metronidazole 0.75% in Cleoderm™ Cream Base .....	99
Phytic Acid 2.0% and Glycolic Acid 2.0% in Cleoderm™ Cream Base .....	100
Phytic Acid 2.0% and Hydroquinone 2.0% in Cleoderm™ Cream Base .....	101
Phytic Acid 2.0% and Kojic Acid 1.0% in Cleoderm™ Cream Base .....	102
Silymarin 1.0%, MSM 5.0%, Vitamin A 0.1%, and Vitamin E 0.5% in Cleoderm™ Cream Base .....	103
Tretinoin 0.01% and Clindamycin (Phosphate) 1.0% in Cleoderm™ Cream Base .....	104
Tretinoin 0.01% and Erythromycin 1.0% in Cleoderm™ Cream Base .....	105
Tretinoin 0.05% and Erythromycin 5.0% in Cleoderm™ Cream Base .....	106
Tretinoin 0.0125% and Niacinamide 4.0% in Cleoderm™ Cream Base .....	107
Tretinoin 0.035% and Niacinamide 6.0% in Cleoderm™ Cream Base .....	108
Zinc (Acetate) 1.2% and Erythromycin 1.0% in Cleoderm™ Cream Base .....	109
Zinc Pyrithione 0.5% and Ketoconazole 2.0% in Cleoderm™ Cream Base .....	110
<b>References .....</b>	<b>111</b>



## Introduction

Dermatological skin conditions are a large number of clinical manifestations that can affect between 30% and 70% of the population worldwide,<sup>1</sup> and they can vary greatly in symptoms and severity. In the United States, they can affect one for every three Americans, and in 2013, skin diseases were responsible for \$ 75 billion costs to the healthcare system.<sup>2,3</sup> In Europe, more than 40% of the population have already reported some kind of skin condition.<sup>1</sup> Some of these conditions can present more or less impact on quality of life of different individuals, and their knowledge is of high importance to determine the diagnosis, as well as the adequate treatment, both professional and home care.<sup>1</sup> Acne, rosacea, dermatitis, and hyperpigmentation are among the most common ones, and they can affect the patient simultaneously, or as a consequence of each other.<sup>1,2</sup>

Some conditions can have a genetic background, and others can be a result of lifestyle and other external causes, but in any case, adequate treatment is a key to improving the life quality of patients.

Most of these conditions respond well to topical treatments, especially the personalized ones, and the adequate choice of the vehicle to compound those treatments is paramount to ensure their success.

**Cleoderm™** is a topical cream designed to be used as a vehicle for compounding of personalized dermatological treatments. Its ingredient profile was specifically designed to be gentle on the skin to allow for its use as a vehicle for compounded preparations that may be applied to the face. **Cleoderm™** has a positive role in decreasing sebum production, lipid peroxidation, and reactive oxygen species, as well as inhibition of *Cutibacterium acnes* proliferation, and control of inflammation. The ingredient profile of **Cleoderm™** makes it a good choice as a vehicle for topical use for inflammatory skin conditions, or conditions in which inflammation can worsen its severity.

## Meet the Cleoderm™ ingredients

**Cleoderm™** is a functional vehicle with selected ingredients that makes it the ideal choice for compounding topical treatments for affected and sensitive skin. Its main constituents are *Cleome gynandra* L. leaf extract, palmitoyl tripeptide-8, bisabolol, hyaluronic acid, and functional oils. This unique combination of ingredients provides **Cleoderm™** with great anti-inflammatory and humectant properties as well as sebum reduction.

### Advantages of choosing Cleoderm™

- Highly spreadable on the skin
- Light skin feel
- Readily absorbed
- Non-comedogenic
- Specially developed for affected skin
- Ideal for oily and acneic skin
- Ideal for whitening treatments
- Anti-inflammatory and anti-redness
- Dermatologically tested



### **Cleome gynandra L. leaf extract**

Known by common names such as Gynandropsis, cat's whisker, and African spider flower, *C. gynandra* has anti-inflammatory and antioxidant properties, as well as positive effects on skin regeneration and allergies.<sup>4-7</sup> **Cleoderm™** uses a patented *C. gynandra* extract, with specific diluents, rich in polyphenols such as rutin and hydroxycinnamic acid. These substances can act synergistically, decreasing sebum secretion and reducing skin inflammation associated with acne.<sup>8-10</sup>



### **Palmitoyl tripeptide-8**

This ingredient is a functional lipopeptide derived from neuromediators, with good anti-inflammatory and soothing properties to the skin. It is excellent for reducing irritation caused by UV radiation and inflammatory cytokines, therefore improving redness, flushing, overall appearance, and sensitiveness of the skin.



### **Bisabolol**

Potent antioxidant, anti-inflammatory, and antibacterial that can restore suppleness and protect the skin against daily environmental stress. It can reduce pro-inflammatory cytokines, therefore improving the condition of irritated skin and ameliorating its aspect. In addition, bisabolol can improve the percutaneous absorption of active ingredients, enhancing the efficacy of different topical treatments.<sup>11-14</sup>



### **Hyaluronic acid**

Hyaluronic acid promote covering to the stratum corneum, preventing water loss from the skin, acting as a moisturizer. Hyaluronic acid has shown a wide range of activities on the skin, such as buffering, anti-inflammatory, antibacterial, antioxidant, and regenerative.<sup>15-20</sup>





### Functional oils


Functional oils are natural substances extracted from plants, rich in chemical compounds that can interact directly with the skin when applied topically, providing multiple benefits according to their properties. **Cleoderm™** has a unique blend of functional oils, carefully chosen for optimal effect and sensory experience.

- **Persea gratissima oil (avocado)**: rich in fatty acids, vitamins, minerals, and oligoelements, has positive effects in maintaining the skin barrier and decreasing exfoliation<sup>21</sup>, with positive effects on acne and atopic dermatitis;<sup>22,23</sup>
- **Simmondsia chinensis seed oil (jojoba)**: positive effect on improving the skin barrier condition, ameliorating acne conditions, psoriasis, rosacea, and wound healing;<sup>24-26</sup>
- **Rosa canina flower oil (dog rose)**: rich in vitamin C, it is a potent antioxidant, anti-inflammatory, and antimicrobial, also with a positive effect on eczema;<sup>27-30</sup>
- **Cocos nucifera oil (coconut)**: presents a marked wound healing capacity, anti-inflammatory, and antimicrobial effect;<sup>31-33</sup>
- **Lavandula angustifolia herb oil (English lavender)**: calming effect, with the capacity of relieving symptoms of irritating conditions such as psoriasis, dermatitis, eczema, and skin allergies;<sup>34-35</sup>
- **Melaleuca alternifolia leaf oil (tea tree)**: presents a range of positive effects on the skin such as antioxidant, amelioration of acne vulgaris due to its anti-inflammatory and antimicrobial properties, improvement of seborrheic dermatitis, and skin regeneration;<sup>36-40</sup>
- **Rosmarinus officinalis leaf oil (rosemary)**: potent antioxidant and anti-inflammatory activities;<sup>41,42</sup>
- **Vitellaria paradoxa butter (shea tree)**: good anti-inflammatory and anti-aging properties, with a positive role in skin regeneration and oxidative damage;<sup>43,44</sup>
- **Tocopheryl acetate (vitamin E)**: potent antioxidant and protector of the skin barrier.<sup>45,46</sup>

## Compounding with Cleoderm™

**Cleoderm™** is an easy-to-compound-with vehicle, compatible with a wide range of active pharmaceutical and dermatological ingredients (APIs and DCIs), and different associations. Up to 10% of solvents or levigants can be added to assist the compounding without affecting the final stability of the formulation.

The final product can be compounded by combining the APIs/DCIs, solvents, and **Cleoderm™** in an appropriate size FagronLab™ mixing jar, mixing for 3 to 4 minutes in the respective FagronLab™ EMP mixing machine, at a medium rotation speed. Process through an ointment mill if needed.







## o Adapalene 0.1% to 0.3% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Adapalene	0.1% to 0.3% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API, the ethoxydiglycol, and the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at room temperature, in a tightly closed container, protected from sunlight.



### Beyond-use date

0.1% 180 days\*; 0.3% 120 days\*

\*The Beyond-Use Date was determined using HPLC stability-indicating method. Additional information available upon request.





**Formula amount**

100 g



**Prescription**

Ingredients	Quantity
Alfa-arbutin	0.5% to 2.0% (w/w)
Cleoderm™, q.s.	100%



**Compounding Instructions**

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



**Storage**

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



**Beyond-use date**

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Alfa-bisabolol 0.5% to 2.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Alfa-bisabolol	0.5% to 2.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





**Formula amount**  
100 g



**Prescription**

Ingredients	Quantity
Ascorbic Acid	5.0% to 20.0% (w/w)
Propanediol	5.0% to 10.0% (w/w)
Cleoderm™, q.s.	100%



**Compounding Instructions**

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API, the propanediol, and the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



**Storage**

Store at room temperature, in a tightly closed container, protected from sunlight.



**Beyond-use date**

5.0% 35 days\*; 20.0% 150 days\*\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.

\*\*The Beyond-Use Date was determined using HPLC stability-indicating method. Additional information available upon request.



## o Azelaic Acid 10.0% to 25.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Azelaic Acid	10.0% to 25.0% (w/w)
Ethoxydiglycol	10.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Wet the API with the ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





## Formula amount

100 g



## Prescription

Ingredients	Quantity
Benzoyl Peroxide 70%	2.5% to 10.0% (w/w)
Cleoderm™, q.s.	100%



## Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



## Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



## Beyond-use date

180 days\*

\*The Beyond-Use Date was determined using HPLC stability-indicating method. Additional information available upon request.



## ○ Brimonidine 0.2% to 0.5% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Brimonidine Tartrate	0.2% to 0.5% (w/w)
Propanediol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API, the propanediol, and the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at room temperature, in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





## Formula amount

100 g



## Prescription

Ingredients	Quantity
Clindamycin (as Phosphate)	1.0% to 3.0% (w/w)
Ethoxydiglycol	10.0% (w/w)
Cleoderm™, q.s.	100%



## Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API, the ethoxydiglycol, and the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



## Storage

Store at room temperature, in a tightly closed container, protected from sunlight.



## Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Clobetasol Propionate 0.5% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Clobetasol (as Propionate)	0.5% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API, the ethoxydiglycol, and the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at room temperature, in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





## Formula amount

100 g



## Prescription

Ingredients	Quantity
Cyproterone Acetate	0.5% to 2.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



## Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API, the ethoxydiglycol, and the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



## Storage

Store at room temperature, in a tightly closed container, protected from sunlight.



## Beyond-use date

180 days\*

\*The Beyond-Use Date was determined using HPLC stability-indicating method. Additional information available upon request.



## o Cysteamine 5.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Cysteamine	5.0% (w/w)
Ethoxydiglycol	10.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API, the ethoxydiglycol, and the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at room temperature, in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





## Formula amount

100 g



## Prescription

Ingredients	Quantity
Dapsone	5.0% to 10.0% (w/w)
Ethoxydiglycol	10.0% (w/w)
Cleoderm™, q.s.	100%



## Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API, the ethoxydiglycol, and the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



## Storage

Store at room temperature, in a tightly closed container, protected from sunlight.



## Beyond-use date

180 days\*

\*The Beyond-Use Date was determined using HPLC stability-indicating method. Additional information available upon request.



## o Ellagic Acid 0.25% to 1.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Ellagic Acid	0.25% to 1.0% (w/w)
DMSO (Dimethylsulfoxide)	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Wet the API with DMSO.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





**Formula amount**

100 g



**Prescription**

Ingredients	Quantity
Enoxolone	0.5% to 2.5% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



**Compounding Instructions**

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Wet the API with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



**Storage**

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



**Beyond-use date**

30 days\*

\*The Beyond-Use Date was determined using HPLC stability-indicating method. Additional information available upon request.



## o Erythromycin 1.0% to 4.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Erythromycin	1.0% to 4.0% (w/w)
Ethoxydiglycol	10.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API, the ethoxydiglycol, and the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at room temperature, in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





**Formula amount**

100 g



**Prescription**

Ingredients	Quantity
Estriol	0.1% to 1.0% (w/w)
Ethoxydiglycol	10.0% (w/w)
Cleoderm™, q.s.	100%



**Compounding Instructions**

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API, the ethoxydiglycol, and the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



**Storage**

Store at room temperature, in a tightly closed container, protected from sunlight.



**Beyond-use date**

180 days\*

\*The Beyond-Use Date was determined using HPLC stability-indicating method. Additional information available upon request.



## o Flutamide 2.0% to 2.5% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Flutamide	2.0% to 2.5% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





## Formula amount

100 g



## Prescription

Ingredients	Quantity
Glycolic Acid 70%	2.0% to 10.0% (w/w)
Cleoderm™, q.s.	100%



## Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



## Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



## Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Hydroquinone 2.0% to 10.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Hydroquinone	2.0% to 10.0% (w/w)
Sodium Metabisulfite	0.3% (w/w)
BHT (Butylated Hydroxytoluene)	0.3% (w/w)
Citric Acid	1.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine all the ingredients with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at room temperature, in a tightly closed container, protected from sunlight.



### Beyond-use date

2.0% 90 days\*; 10.0% 180 days\*

\*The Beyond-Use Date was determined using HPLC stability-indicating method. Additional information available upon request.





**Formula amount**

100 g



**Prescription**

Ingredients	Quantity
Isotretinoin USP	0.05% (w/w)
BHT (Butylated Hydroxytoluene)	0.1% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



**Compounding Instructions**

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



**Storage**

Store at room temperature, in a tightly closed container, protected from sunlight.



**Beyond-use date**

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Kojic Acid 1.0% to 4.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Kojic Acid	1.0% to 4.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Wet the API with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





## Formula amount

100 g



## Prescription

Ingredients	Quantity
Mandelic Acid	2.0% to 10.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



## Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API, the ethoxydiglycol, and the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



## Storage

Store at room temperature, in a tightly closed container, protected from sunlight.



## Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Metronidazole 0.75% to 5.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Metronidazole	0.75% to 5.0% (w/w)
Ethoxydiglycol	10.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API, the ethoxydiglycol, and the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at room temperature, in a tightly closed container, protected from sunlight.



### Beyond-use date

180 days\*

\*The Beyond-Use Date was determined using HPLC stability-indicating method. Additional information available upon request.





## Formula amount

100 g



## Prescription

Ingredients	Quantity
Miconazole Nitrate	0.25% to 2.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



## Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



## Storage

Store at room temperature, in a tightly closed container, protected from sunlight.



## Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o N-Acetylcysteine 3.0% to 5.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
N-Acetylcysteine	3.0% to 5.0% (w/w)
Ethoxydiglycol	10.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at room temperature, in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





**Formula amount**

100 g



**Prescription**

Ingredients	Quantity
Niacinamide	1.0% to 5.0% (w/w)
Ethoxydiglycol	10.0% (w/w)
Cleoderm™, q.s.	100%



**Compounding Instructions**

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API, the ethoxydiglycol, and the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



**Storage**

Store at room temperature, in a tightly closed container, protected from sunlight.



**Beyond-use date**

180 days\*

\*The Beyond-Use Date was determined using HPLC stability-indicating method. Additional information available upon request.



## o Permethrin 1.0% to 5.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Permethrin	1.0% to 5.0% (w/w)
Ethoxydiglycol	10.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API, the ethoxydiglycol, and the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at room temperature, in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





**Formula amount**

100 g



**Prescription**

Ingredients	Quantity
Phytic Acid	2.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



**Compounding Instructions**

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API, the ethoxydiglycol, and the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



**Storage**

Store at room temperature, in a tightly closed container, protected from sunlight.



**Beyond-use date**

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Progesterone 0.5% to 2.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Progesterone Micro	0.5% to 2.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API, the ethoxydiglycol, and the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at room temperature, in a tightly closed container, protected from sunlight.



### Beyond-use date

180 days\*

\*The Beyond-Use Date was determined using HPLC stability-indicating method. Additional information available upon request.





**Formula amount**

100 g



**Prescription**

Ingredients	Quantity
Silymarin	1.0% to 16.0% (w/w)
Ethoxydiglycol	10.0% (w/w)
Cleoderm™, q.s.	100%



**Compounding Instructions**

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API, the ethoxydiglycol, and the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



**Storage**

Store at room temperature, in a tightly closed container, protected from sunlight.



**Beyond-use date**

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Spironolactone 1.0% to 5.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Spironolactone	1.0% to 5.0% (w/w)
Ethoxydiglycol	10.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API, the ethoxydiglycol, and the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at room temperature, in a tightly closed container, protected from sunlight.



### Beyond-use date

180 days\*

\*The Beyond-Use Date was determined using HPLC stability-indicating method. Additional information available upon request.





**Formula amount**

100 g



**Prescription**

Ingredients	Quantity
Tazarotene	0.045% to 0.1% (w/w)
Cleoderm™, q.s.	100%



**Compounding Instructions**

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



**Storage**

Store at room temperature, in a tightly closed container, protected from sunlight.



**Beyond-use date**

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Tranexamic Acid 1.0% to 5.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Tranexamic Acid	1.0% to 5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at room temperature, in a tightly closed container, protected from sunlight.



### Beyond-use date

180 days\*

\*The Beyond-Use Date was determined using HPLC stability-indicating method. Additional information available upon request.





**Formula amount**

100 g



**Prescription**

Ingredients	Quantity
Tretinoin	0.01% to 0.1% (w/w)
BHT (Butylated Hydroxytoluene)	0.1% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



**Compounding Instructions**

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API, the ethoxydiglycol, the BHT, and the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



**Storage**

Store at room temperature, in a tightly closed container, protected from sunlight.



**Beyond-use date**

30 days\*

\*The Beyond-Use Date was determined using HPLC stability-indicating method. Additional information available upon request.



## o Zinc Acetate 1.2% to 1.5% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Zinc Acetate	1.2% to 1.5% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine the API, the ethoxydiglycol, and the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
3. Process through Three Roll/Ointment Mill as needed.
4. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at room temperature, in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





## Formula amount

100 g



## Prescription

Ingredients	Quantity
Zinc Pyrithione	0.5% to 2.0% (w/w)
Ethoxydiglycol	10.0% (w/w)
Cleoderm™, q.s.	100%



## Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Wet the API with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



## Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



## Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.







## o Adapalene 0.1% and Benzoyl Peroxide 1.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Adapalene	0.1% (w/w)
Benzoyl Peroxide 70%	1.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





**Formula amount**

100 g



**Prescription**

Ingredients	Quantity
Adapalene	0.3% (w/w)
Benzoyl Peroxide 70%	10.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



**Compounding Instructions**

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



**Storage**

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



**Beyond-use date**

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Adapalene 0.15%, Clindamycin (Phosphate) 1.2%, and Benzoyl Peroxide 3.1% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Adapalene	0.15% (w/w)
Clindamycin (as Phosphate)	1.2% (w/w)
Benzoyl Peroxide 70%	3.1% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





## Formula amount

100 g



## Prescription

Ingredients	Quantity
Alfa-arbutin	0.5% (w/w)
Ascorbic Acid	5.0% (w/w)
Propanediol	10.0% (w/w)
Cleoderm™, q.s.	100%



## Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with propanediol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



## Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



## Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Alfa-arbutin 0.5% and Glycolic Acid 2.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Alfa-arbutin	0.5% (w/w)
Glycolic Acid 70%	2.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





## Formula amount

100 g



## Prescription

Ingredients	Quantity
Alfa-arbutin	0.5% (w/w)
Hydroquinone	2.0% (w/w)
BHT (Butylated Hydroxytoluene)	0.1% (w/w)
Citric Acid	0.8% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



## Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



## Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



## Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Alfa-arbutin 0.5% and Kojic Acid 1.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Alfa-arbutin	0.5% (w/w)
Kojic Acid	1.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





**Formula amount**

100 g



**Prescription**

Ingredients	Quantity
Alfa-arbutin	0.5% (w/w)
Mandelic Acid	2.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



**Compounding Instructions**

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



**Storage**

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



**Beyond-use date**

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Alfa-arbutin 0.5% and Phytic Acid 0.05% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Alfa-arbutin	0.5% (w/w)
Phytic Acid	0.05% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





**Formula amount**

100 g



**Prescription**

Ingredients	Quantity
Alfa-bisabolol	0.5% (w/w)
Glycolic Acid 70%	2.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



**Compounding Instructions**

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



**Storage**

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



**Beyond-use date**

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Alfa-bisabolol 0.5% and Tretinoin 0.01% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Alfa-bisabolol	0.5% (w/w)
Tretinoin	0.01% (w/w)
BHT (Butylated Hydroxytoluene)	0.1% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





## Formula amount

100 g



## Prescription

Ingredients	Quantity
Ascorbic Acid	5.0% (w/w)
Glycolic Acid 70%	2.0% (w/w)
Propanediol	10.0% (w/w)
Cleoderm™, q.s.	100%



## Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with propanediol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



## Storage

Store at a controlled room temperature (20°C to 25°C), in a tightly closed container, protected from sunlight.



## Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Ascorbic Acid 5.0% and Niacinamide 1.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Ascorbic Acid	5.0% (w/w)
Niacinamide	1.0% (w/w)
Propanediol	10.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with propanediol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





## Formula amount

100 g



## Prescription

Ingredients	Quantity
Ascorbic Acid	5.0% (w/w)
Salicylic Acid	0.5% (w/w)
Propanediol	10.0% (w/w)
Cleoderm™, q.s.	100%



## Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with propanediol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



## Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



## Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Azelaic Acid 10.0% and Erythromycin 1.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Azelaic Acid	10.0% (w/w)
Erythromycin	1.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





**Formula amount**

100 g



**Prescription**

Ingredients	Quantity
Azelaic Acid	10.0% (w/w)
Niacinamide	1.0% (w/w)
Propanediol	5.0% (w/w)
Ethyl alcohol	2.5% (w/w)
Cleoderm™, q.s.	100%



**Compounding Instructions**

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Triturate the APIs with propanediol and ethyl alcohol until smooth (for best results, mix for 1-2 minutes in an EMP mixing device).
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



**Storage**

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



**Beyond-use date**

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Azelaic Acid 15.0% and Niacinamide 4.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Azelaic Acid	15.0% (w/w)
Niacinamide	4.0% (w/w)
Propanediol	10.0% (w/w)
Ethyl alcohol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Triturate the APIs with propanediol and ethyl alcohol until smooth (for best results, mix for 1-2 minutes in an EMP mixing device).
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





## Formula amount

100 g



## Prescription

Ingredients	Quantity
Benzoyl Peroxide 70%	2.5% (w/w)
Erythromycin	1.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



## Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



## Storage

Store at a controlled room temperature (20°C to 25°C), in a tightly closed container, protected from sunlight.



## Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Clindamycin (Phosphate) 1.0% and Adapalene 0.1% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Clindamycin (as Phosphate)	1.0% (w/w)
Adapalene	0.1% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



# Clindamycin (Phosphate) 1.0%, Benzoyl Peroxide 1.0%, and Niacinamide 1.0% in Cleoderm™ Cream Base



## Formula amount

100 g



## Prescription

Ingredients	Quantity
Clindamycin (as Phosphate)	1.0% (w/w)
Benzoyl Peroxide 70%	1.0% (w/w)
Niacinamide	1.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



## Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



## Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



## Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Clindamycin (Phosphate) 3.0%, Benzoyl Peroxide 10.0%, and Niacinamide 4.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Clindamycin (as Phosphate)	3.0% (w/w)
Benzoyl Peroxide 70%	10.0% (w/w)
Niacinamide	4.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



# Clindamycin (Phosphate) 1.0% and Hydroquinone 4.0% in Cleoderm™ Cream Base



**Formula amount**  
100 g



## Prescription

Ingredients	Quantity
Clindamycin (as Phosphate)	1.0% (w/w)
Hydroquinone	4.0% (w/w)
Ethoxydiglycol	10% (w/w)
BHT (Butylated Hydroxytoluene)	0.1% (w/w)
Sodium Metabisulfite	0.3% (w/w)
Citric Acid	0.8% (w/w)
Cleoderm™, q.s.	100%



## Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs and antioxidants with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



## Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



## Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Clindamycin (Phosphate) 1.0% and Tretinoin 0.01% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Clindamycin (as Phosphate)	1.0% (w/w)
Tretinoin	0.01% (w/w)
BHT (Butylated Hydroxytoluene)	0.1% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



# Clobetasol Propionate 0.05%, Hydroquinone 2.0%, and Tretinoin 0.01% in Cleoderm™ Cream Base



## Formula amount

100 g



## Prescription

Ingredients	Quantity
Clobetasol Ppropionate	0.05% (w/w)
Hydroquinone	2.0% (w/w)
Tretinoin	0.01% (w/w)
BHT (Butylated Hydroxytoluene)	0.1% (w/w)
Citric Acid	0.8% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



## Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



## Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



## Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Cysteamine 5.0% and Niacinamide 1.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Cysteamine	5.0% (w/w)
Niacinamide	1.0% (w/w)
Ethoxydiglycol	10.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





**Formula amount**

100 g



**Prescription**

Ingredients	Quantity
Cysteamine	5.0% (w/w)
Tranexamic Acid	1.0% (w/w)
Ethoxydiglycol	10.0% (w/w)
Cleoderm™, q.s.	100%



**Compounding Instructions**

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



**Storage**

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



**Beyond-use date**

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Dapsone 5.0% and Adapalene 0.1% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Dapsone	5.0% (w/w)
Adapalene	0.1% (w/w)
Ethoxydiglycol	10.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





## Formula amount

100 g



## Prescription

Ingredients	Quantity
Enoxolone	0.5% (w/w)
Glycolic Acid 70%	2.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



## Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



## Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



## Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Enoxolone 0.5% and Metronidazole 0.75% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Enoxolone	0.5% (w/w)
Metronidazole	0.75% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





**Formula amount**

100 g



**Prescription**

Ingredients	Quantity
Enoxolone	0.5% (w/w)
Tretinoin	0.01% (w/w)
BHT (Butylated Hydroxytoluene)	0.1% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



**Compounding Instructions**

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



**Storage**

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



**Beyond-use date**

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



o **Glycolic Acid 2.0%  
and Clindamycin (Phosphate) 1.0% in Cleoderm™ Cream Base**



**Formula amount**  
100 g



**Prescription**

Ingredients	Quantity
Glycolic Acid 70%	2.0% (w/w)
Clindamycin (as Phosphate)	1.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



**Compounding Instructions**

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



**Storage**

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



**Beyond-use date**  
35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





## Formula amount

100 g



## Prescription

Ingredients	Quantity
Glycolic Acid 70%	2.0% (w/w)
Erythromycin	1.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



## Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



## Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



## Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



**o Glycolic Acid 5.0%, Gluconolactone 2.5%, Mandelic Acid 2.5%, and Salicylic Acid 0.5% in Cleoderm™ Cream Base**



**Formula amount**

100 g



**Prescription**

Ingredients	Quantity
Glycolic Acid 70%	5.0% (w/w)
Gluconolactone	2.5% (w/w)
Mandelic Acid	2.5% (w/w)
Salicylic Acid	0.5% (w/w)
Ethoxydiglycol	10.0% (w/w)
Cleoderm™, q.s.	100%



**Compounding Instructions**

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



**Storage**

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



**Beyond-use date**

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





**Formula amount**

100 g



**Prescription**

Ingredients	Quantity
Glycolic Acid 70%	2.0% (w/w)
Tretinoin	0.01% (w/w)
BHT (Butylated Hydroxytoluene)	0.1% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



**Compounding Instructions**

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



**Storage**

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



**Beyond-use date**

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Hydrocortisone 1.0%, Hydroquinone 4.0%, Tranexamic Acid 2.5%, and Tretinoin 0.0125% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Hydrocortisone	1.0% (w/w)
Hydroquinone	4.0% (w/w)
Tranexamic Acid	2.5% (w/w)
Tretinoin USP	0.0125% (w/w)
Ethoxydiglycol	10.0% (w/w)
BHT (Butylated Hydroxytoluene)	0.1% (w/w)
Citric Acid	0.8% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs and antioxidants with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



# Hydrocortisone 1.0%, Hydroquinone 4.0%, Tranexamic Acid 2.5%, and Tretinoin 0.035% in Cleoderm™ Cream Base



## Formula amount

100 g



## Prescription

Ingredients	Quantity
Hydrocortisone	1.0% (w/w)
Hydroquinone	4.0% (w/w)
Tranexamic Acid	2.5% (w/w)
Tretinoin	0.035% (w/w)
Ethoxydiglycol	10.0% (w/w)
BHT (Butylated Hydroxytoluene)	0.1% (w/w)
Citric Acid	0.8% (w/w)
Cleoderm™, q.s.	100%



## Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs and antioxidants with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



## Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



## Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Isotretinoin 0.05% and Erythromycin 2.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Isotretinoin	0.05% (w/w)
Erythromycin	2.0% (w/w)
BHT (Butylated Hydroxytoluene)	0.1% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





## Formula amount

100 g



## Prescription

Ingredients	Quantity
Mandelic Acid	2.0% (w/w)
Benzoyl Peroxide 70%	2.5% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



## Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



## Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



## Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Mandelic Acid 2.0% and Tretinoin 0.01% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Mandelic Acid	2.0% (w/w)
Tretinoin	0.01% (w/w)
BHT (Butylated Hydroxytoluene)	0.1% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





**Formula amount**

100 g



**Prescription**

Ingredients	Quantity
Metronidazole	0.75% (w/w)
Alfa-bisabolol	0.5% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



**Compounding Instructions**

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



**Storage**

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



**Beyond-use date**

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Metronidazole 0.75% and Azelaic Acid 1.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Metronidazole	0.75% (w/w)
Azelaic Acid	1.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



# Metronidazole 0.75% and Clindamycin (Phosphate) 1.0% in Cleoderm™ Cream Base



## Formula amount

100 g



## Prescription

Ingredients	Quantity
Metronidazole	0.75% (w/w)
Clindamycin (as Phosphate)	1.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



## Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



## Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



## Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Metronidazole 0.75% and Erythromycin 1.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Metronidazole	0.75% (w/w)
Erythromycin	1.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





## Formula amount

100 g



## Prescription

Ingredients	Quantity
Metronidazole	0.75% (w/w)
Niacinamide	1.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



## Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



## Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



## Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Metronidazole 2.0% and Niacinamide 5.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Metronidazole	2.0% (w/w)
Niacinamide	5.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





## Formula amount

100 g



## Prescription

Ingredients	Quantity
Metronidazole	0.75% (w/w)
Tretinoin	0.01% (w/w)
BHT (Butylated Hydroxytoluene)	0.1% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



## Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



## Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



## Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## Miconazole (Nitrate) 0.25% and Benzoyl Peroxide 2.5% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Miconazole (as Nitrate)	0.25% (w/w)
Benzoyl Peroxide 70%	2.5% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





## Formula amount

100 g



## Prescription

Ingredients	Quantity
Miconazole (as Nitrate)	0.25% (w/w)
Erythromycin	1.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



## Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



## Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



## Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Miconazole (Nitrate) 0.25% and Zinc Oxide 10.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Miconazole (as Nitrate)	0.25% (w/w)
Zinc Oxide (15% as paste)	10.0% (w/w)
Ethoxydiglycol	10.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





**Formula amount**

100 g



**Prescription**

Ingredients	Quantity
Permethrin	1.0% (w/w)
Metronidazole	0.75% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



**Compounding Instructions**

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



**Storage**

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



**Beyond-use date**

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Phytic Acid 2.0% and Glycolic Acid 2.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Phytic Acid	2.0% (w/w)
Glycolic Acid 70%	2.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





**Formula amount**

100 g



**Prescription**

Ingredients	Quantity
Phytic Acid	2.0% (w/w)
Hydroquinone	2.0% (w/w)
BHT (Butylated Hydroxytoluene)	0.1% (w/w)
Citric Acid	0.8% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



**Compounding Instructions**

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



**Storage**

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



**Beyond-use date**

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Phytic Acid 2.0% and Kojic Acid 1.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Phytic Acid	2.0% (w/w)
Kojic Acid	1.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## Silymarin 1.0%, MSM 5.0%, Vitamin A 0.1%, and Vitamin E 0.5% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Silymarin	1.0% (w/w)
MSM (Methyl Sulfonylmethane)	5.0% (w/w)
Vitamin A (Oil)	0.1% (w/w)
Vitamin E (Oil)	0.5% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Tretinoin 0.01% and Clindamycin (Phosphate) 1.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Tretinoin	0.01% (w/w)
Clindamycin (as Phosphate)	1.0% (w/w)
BHT (Butylated Hydroxytoluene)	0.1% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs and the antioxidant with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





**Formula amount**

100 g



**Prescription**

Ingredients	Quantity
Tretinoin	0.01% (w/w)
Erythromycin	1.0% (w/w)
BHT (Butylated Hydroxytoluene)	0.1% (w/w)
Sodium Metabisulfite	0.3% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



**Compounding Instructions**

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs and the antioxidant with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



**Storage**

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



**Beyond-use date**

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Tretinoin 0.05% and Erythromycin 5.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Tretinoin	0.05% (w/w)
Erythromycin	5.0% (w/w)
BHT (Butylated Hydroxytoluene)	0.1% (w/w)
Sodium Metabisulfite	0.3% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs and the antioxidant with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





**Formula amount**

100 g



**Prescription**

Ingredients	Quantity
Tretinoin	0.0125% (w/w)
Niacinamide	4.0% (w/w)
BHT (Butylated Hydroxytoluene)	0.1% (w/w)
Ethoxydiglycol	10.0% (w/w)
Cleoderm™, q.s.	100%



**Compounding Instructions**

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs and the antioxidant with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



**Storage**

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



**Beyond-use date**

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Tretinoin 0.035% and Niacinamide 6.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Tretinoin	0.035% (w/w)
Niacinamide	6.0% (w/w)
BHT (Butylated Hydroxytoluene)	0.1% (w/w)
Ethoxydiglycol	10.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs and the antioxidant with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.





**Formula amount**

100 g



**Prescription**

Ingredients	Quantity
Zinc (as Acetate)	1.2% (w/w)
Erythromycin	1.0% (w/w)
Propanediol	5.0% (w/w)
Cleoderm™, q.s.	100%



**Compounding Instructions**

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



**Storage**

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



**Beyond-use date**

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## o Zinc Pyrithione 0.5% and Ketoconazole 2.0% in Cleoderm™ Cream Base



### Formula amount

100 g



### Prescription

Ingredients	Quantity
Zinc Pyrithione	0.5% (w/w)
Ketoconazole	2.0% (w/w)
Ethoxydiglycol	5.0% (w/w)
Cleoderm™, q.s.	100%



### Compounding Instructions

1. Calculate and weigh the required quantity of the ingredients for the total amount to be prepared.
2. Combine and wet the APIs with ethoxydiglycol.
3. Combine with the Cleoderm™ cream base in an appropriate size EMP jar, then mix for 3-4 minutes in an EMP mixing device, at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.



### Storage

Store at a controlled room temperature (20 °C to 25 °C), in a tightly closed container, protected from sunlight.



### Beyond-use date

35 days\*

\*Estimated beyond-use date. In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for preserved aqueous dosage forms.



## References

1. Richard MA, Paul C, Nijsten T, et al. Prevalence of most common skin diseases in Europe: a population-based study. *J Eur Acad Dermatol Venereol*. 2022;36(7):1088-1096. doi:10.1111/jdv.18050
2. National Center for Complementary and Integrative Health. Skin Conditions at a Glance. Published 2019. Accessed August 12, 2022. [https://www.nccih.nih.gov/health/skin-conditions-at-a-glance#:~:text=Skin diseases are very common,called eczema\)%2C and psoriasis.](https://www.nccih.nih.gov/health/skin-conditions-at-a-glance#:~:text=Skin diseases are very common,called eczema)%2C and psoriasis.)
3. Lim HW, Collins SAB, Resneck JS, et al. A risk adjustment approach to estimating the burden of skin disease in the United States. *J Am Acad Dermatol*. 2018;78(1):129-140. doi:10.1016/j.jaad.2017.08.060
4. Neamsuvan O, Bunmee P. A survey of herbal weeds for treating skin disorders from Southern Thailand: Songkhla and Krabi Province. *J Ethnopharmacol*. 2016;193:574-585. doi:10.1016/j.jep.2016.09.048
5. Anbazhagi T, Kadavul K, Suguna G, Petrus AJA. Studies on the pharmacognostical and in vitro antioxidant potential of cleome gynandra Linn. leaves. *Nat Prod Radiance*. 2009;8(2):151-157.
6. Shanmugam S, Rajendran K, Suresh K. Traditional uses of medicinal plants among the rural people in Sivagangai district of Tamil Nadu, Southern India. *Asian Pac J Trop Biomed*. 2012;2(1):S429-S434. doi:10.1016/S2221-1691(12)60201-9
7. Santosh KM, Seth A. Potential medicinal plants and traditional ayurvedic approach towards Urticaria, an allergic skin disorder. *Int J Pharm Pharm Sci*. 2014;6(5):172-177.
8. Gaur K, Kori ML, Nema RK. Comparative Screening of Immunomodulatory Activity of Hydro-alcoholic Extract of Hibiscus rosa sinensis Linn. and Ethanolic Extract of Cleome gynandra Linn. *Glob J Pharmacol*. 2009;3(2):85-89.
9. Narendhirakannan RT, Subramanian S, Kandaswamy M. Anti-inflammatory and lysosomal stability actions of Cleome gynandra L. studied in adjuvant induced arthritic rats. *Food Chem Toxicol*. 2007;45(6):1001-1012. doi:10.1016/j.fct.2006.12.009
10. Mishra SS, Moharana SK, Dash MR. Review on cleome gynandra. *Int J Res Pharm Chem*. 2011;(July 2011).
11. Kim EJ, Park H, Kim J, Park JHY. 3,3'-diindolylmethane suppresses 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and tumor promotion in mouse skin via the downregulation of inflammatory mediators. *Mol Carcinog*. 2010;49(7):672-683. doi:10.1002/mc.20640
12. Villegas LF, Marçalo A, Martin J, et al. (+)-epi-Bisabolol Is the Wound-Healing Principle of Peperomia gaioidea: Investigation of the in Vivo Wound-Healing Activity of Related Terpenoids. *J Nat Prod*. 2001;64(10):1357-1359. doi:10.1021/np0102859
13. Kamatou GPP, Viljoen AM. A Review of the Application and Pharmacological Properties of Bisabolol and Bisabolol-Rich Oils. *J Am Oil Chem Soc*. 2010;87(1):1-7. doi:10.1007/s11746-009-1483-3
14. Kadir R, Barry BW. Bisabolol, a possible safe penetration enhancer for dermal and transdermal therapeutics. *Int J Pharm*. 1991;70(1-2):87-94. doi:10.1016/0378-5173(91)90167-M
15. Zhang W, Mu H, Zhang A, et al. A decrease in moisture absorption-retention capacity of N-deacetylation of hyaluronic acid. *Glycoconj J*. 2013;30(6):577-583. doi:10.1007/s10719-012-9457-3
16. Jentsch H, Pomowski R, Kundt G, Göcke R. Treatment of gingivitis with hyaluronan. *J Clin Periodontol*. 2003;30(2):159-164. doi:10.1034/j.1600-051X.2003.300203.x
17. Frenkel JS. The role of hyaluronan in wound healing. *Int Wound J*. 2014;11(2):159-163. doi:10.1111/j.1742-481X.2012.01057.x
18. Huang, Huang, Lew, Fan, Chang, Huang. Gamma-Irradiation-Prepared Low Molecular Weight Hyaluronic Acid Promotes Skin Wound Healing. *Polymers (Basel)*. 2019;11(7):1214. doi:10.3390/polym11071214
19. Voigt J, Driver VR. Hyaluronic acid derivatives and their healing effect on burns, epithelial surgical wounds, and chronic wounds: A systematic review and meta-analysis of randomized controlled trials. *Wound Repair Regen*. 2012;20(3):317-331. doi:10.1111/j.1524-475X.2012.00777.x
20. Neuman MG, Nanau RM, Oruña-Sánchez L, Coto G. Hyaluronic Acid and Wound Healing. *J Pharm Pharm Sci*. 2015;18(1):53. doi:10.18433/J3K89D
21. Ochiuz L, Hortolomei M. Development of Microemulsion Dermal Products Based on Avocado Oil for Topical Administration. *Prop Uses Microemulsions*. Published online 2017. doi:10.5772/66077
22. Kanlayavattanukul M, Lourith N. Therapeutic agents and herbs in topical application for acne treatment. *Int J Cosmet Sci*. Published online 2011. doi:10.1111/j.1468-2494.2011.00647.x
23. Stucker M, Pieck C, Stoerb C, Niedner R, Hartung J, Altmeier P. Topical vitamin B12-a new therapeutic approach in atopic dermatitis-evaluation of efficacy and tolerability in a randomized placebo-controlled multicentre clinical trial. *Br J Dermatol*. 2004;150(5):977-983. doi:10.1111/j.1365-2133.2004.05866.x
24. Meier L, Stange R, Michalsen A, Uehleke B. Clay Jojoba Oil Facial Mask for Lesioned Skin and Mild Acne &#150; Results of a Prospective, Observational Pilot Study. *Forschende Komplementärmedizin / Res Complement Med*. 2012;19(2):75-79. doi:10.1159/000338076
25. Ranzato E, Martinotti S, Burlando B. Wound healing properties of jojoba liquid wax: An in vitro study. *J Ethnopharmacol*. 2011;134(2):443-449. doi:10.1016/j.jep.2010.12.042
26. Vaughn AR, Clark AK, Sivamani RK, Shi VY. Natural Oils for Skin-Barrier Repair: Ancient Compounds Now Backed by Modern Science. *Am J Clin Dermatol*. 2018;19(1):103-117. doi:10.1007/s40257-017-0301-1
27. Kähkönen MP, Hopia AI, Vuorela HJ, et al. Antioxidant Activity of Plant Extracts Containing Phenolic Compounds. *J Agric Food Chem*. 1999;47(10):3954-3962. doi:10.1021/jf990146l
28. Lin T-K, Zhong L, Santiago J. Anti-Inflammatory and Skin Barrier Repair Effects of Topical Application of Some Plant Oils. *Int J Mol Sci*. 2017;19(1):70. doi:10.3390/ijms19010070
29. Shiota S. Restoration of effectiveness of lactams on methicillin-resistant Staphylococcus aureus by tellimagrandin I from rose red. *FEMS Microbiol Lett*. 2000;185(2):135-138. doi:10.1016/S0378-1097(00)00086-0
30. Shabykin GP, Godorazhi AI. A polyvitamin preparation of fat-soluble vitamins (carotolin) and rose hip oil in the treatment of certain dermatoses. *Vestn Dermatol Venereol*. 1967;41(4):71-73. <http://www.ncbi.nlm.nih.gov/pubmed/5629352>



31. Huang CB, Alimova Y, Myers TM, Ebersole JL. Short- and medium-chain fatty acids exhibit antimicrobial activity for oral microorganisms. *Arch Oral Biol.* 2011;56(7):650-654. doi:10.1016/j.archoralbio.2011.01.011
32. Poljšak N, Kreft S, Kočevar Glavač N. Vegetable butters and oils in skin wound healing: Scientific evidence for new opportunities in dermatology. *Phyther Res.* 2020;34(2):254-269. doi:10.1002/ptr.6524
33. Osman A. Coconut (*Cocos nucifera*) Oil. In: *Fruit Oils: Chemistry and Functionality*. Springer International Publishing; 2019:209-221. doi:10.1007/978-3-030-12473-1\_9
34. Cavanagh HMA, Wilkinson JM. Biological activities of Lavender essential oil. *Phyther Res.* 2002;16(4):301-308. doi:10.1002/ptr.1103
35. Kim H-M, Cho S-H. Lavender Oil Inhibits Immediate-type Allergic Reaction in Mice and Rats. *J Pharm Pharmacol.* 2010;51(2):221-226. doi:10.1211/0022357991772178
36. Kim H-J, Chen F, Wu C, Wang X, Chung HY, Jin Z. Evaluation of Antioxidant Activity of Australian Tea Tree (*Melaleuca alternifolia*) Oil and Its Components. *J Agric Food Chem.* 2004;52(10):2849-2854. doi:10.1021/jf035377d
37. Enshaieh S, Jooya A, Siadat AH, Iraj F. The efficacy of 5% topical tea tree oil gel in mild to moderate acne vulgaris: A randomized, double-blind placebo-controlled study. *Indian J Dermatol Venereol Leprol.* Published online 2007. doi:10.4103/0378-6323.30646
38. Bassett IB, Barnetson RSC, Pannowitz DL. A comparative study of tea-tree oil versus benzoylperoxide in the treatment of acne. *Med J Aust.* 1990;153(8):455-458. doi:10.5694/j.1326-5377.1990.tb126150.x
39. Pazyar N, Yaghoobi R, Bagherani N, Kazerouni A. A review of applications of tea tree oil in dermatology. *Int J Dermatol.* 2013;52(7):784-790. doi:10.1111/j.1365-4632.2012.05654.x
40. Jandera V, Hudson DA, de Wet PM, Innes PM, Rode H. Cooling the burn wound: evaluation of different modalities. *Burns.* 2000;26(3):265-270. doi:10.1016/S0305-4179(99)00133-3
41. Takaki I, Bersani-Amado LE, Vendruscolo A, et al. Anti-Inflammatory and Antinociceptive Effects of *Rosmarinus officinalis* L. Essential Oil in Experimental Animal Models. *J Med Food.* 2008;11(4):741-746. doi:10.1089/jmf.2007.0524
42. Altinier G, Sosa S, Aquino RP, Mencherini T, Della Loggia R, Tubaro A. Characterization of topical antiinflammatory compounds in *Rosmarinus officinalis* L. *J Agric Food Chem.* 2007;55(5):1718-1723. doi:10.1021/jf062610+
43. Israel MO. Effects of Topical and Dietary Use of Shea Butter on Animals. *Am J Life Sci.* 2014;2(5):303. doi:10.11648/j.ajls.20140205.18
44. Siegel DM, Jakus J, Hooper D. Topical natural products in managing dermatologic conditions: Observations and recommendations. *Cutis.* 2019;103(4):233-236.
45. Thiele JJ, Hsieh SN, Ekanayake-Mudiyanselage S. Vitamin E: Critical Review of Its Current Use in Cosmetic and Clinical Dermatology. *Dermatologic Surg.* 2006;31:805-813. doi:10.1111/j.1524-4725.2005.31724
46. Keen M, Hassan I. Vitamin E in dermatology. *Indian Dermatol Online J.* 2016;7(4):311. doi:10.4103/2229-5178.185494

## Disclaimer

This document contains examples of some commonly prescribed formulations across a diverse array of specialties, and they are not meant to encourage the use of any formula contained within. The customer is responsible for and, by its receipt of the Example Formula, agrees it will take any and all steps necessary to independently verify any formulation, concentrations, and raw amounts of components provided in this Example Formula, including any formulation that is the same or similar to the Example Formula, that is used in Customer's business to ensure the accuracy of all product components and component concentrations, as well as the compatibility and stability of all formulation components. Fagron, its owners, officers, agents, affiliates, and employees make no representation or warranty whatsoever with respect to these Example Formulas. Customer understands and agrees that Fagron, its owners, officers, agents, affiliates, and employees shall not be responsible for any claims, actions, liabilities, losses, expenses, damages, judgment, or costs arising directly or indirectly or related in any way to any actual or alleged injury to any person (including death) resulting from or claimed to result wholly or in part from any formulation that is the same or similar to any Example Formulas.

**Together**  
we create the future  
of personalizing medicine.



**Fagron BV**  
Fascinatio Boulevard 350  
3065 WB Rotterdam  
The Netherlands

T +31 88 33 11 288  
F +31 88 33 11 210  
[www.fagron.com](http://www.fagron.com)

 **Fagron**  
personalizing  
medicine